CAMK2G and cardiomyopathy: As demonstrated by animal experiments, AC3-I and AIP, as inhibitors of CaMKII, can influence CaMKII activity by genetically engineering the expression of AC3-I in vivo and providing protective effects against cardiomyopathies such as cardiac remodeling.